Skip to main content
IG

ImplantGuard GmbH

This startup develops a bacteria treatment technology and antimicrobials to prevent infections on medical devices. Their technology targets and kills antibiotic-resistant bacteria, and has also shown virucidal activity against coronaviruses on non-porous surfaces, helping to reduce healthcare-associated infections.

Vienna, Austria10+ followers
Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Healthcare-associated infections (HAIs) from bacteria, viruses, and fungi remain a significant threat to patient health despite advances in medical device technology. These infections, including bloodstream infections, pneumonia, urinary tract infections, and surgical site infections, can lead to increased morbidity and mortality. Current methods for preventing device-related infections often lack long-term efficacy and broad-spectrum protection.

Solution

Implant Guard offers a patented surface treatment technology designed to prevent infections on medical devices. The technology bonds antimicrobial and antiviral agents to various materials, including plastics, metals, glass, and ceramics. This non-leaching surface treatment rapidly kills a broad spectrum of bacteria, including antibiotic-resistant strains, and exhibits virucidal activity against coronaviruses. The coating prevents surface colonization and biofilm formation, reducing the risk of HAIs associated with medical implants and devices.

Target Audience

The primary target audience includes medical device manufacturers seeking to enhance the infection resistance of their products, as well as hospitals and healthcare providers aiming to reduce the incidence of healthcare-associated infections.

Features

  • Patented technology for bonding antimicrobial and antiviral agents to medical devices
  • Broad-spectrum efficacy against bacteria, viruses, and fungi
  • Demonstrated effectiveness against antibiotic-resistant bacteria
  • Rapid kill rate, achieving greater than 99.9% efficacy in under 5 minutes in independent laboratory tests
  • Durable coating that remains stable and effective after sterilization (Gamma and Beta)
  • Customizable surface treatment adaptable to any shape of the device
  • Prevents surface colonization, biofilm formation, recontamination, and onward transmission
  • Tested according to ISO 22196 (antibacterial) and ISO 21702:2019 (antiviral) standards
This profile is AI-generated and may contain inaccuracies.